# META FINES

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/meta-fines

- Industry: Biotechnology
- Headquarters: Seongnam, South Korea
- Website: www.metafines.com
- Total disclosed funding: $24M
- Latest round: Series B (Apr 28, 2022)
- Investors on record: 10

## About

Based in South Korea, and founded in 2018, META FINES, INC. operates as a developer of a low-toxic anticancer drug. In April 2022, META FINES, INC. raised KRW 20 billion in series B funding from returning investors DSC Investment and BMIKOREA and new investors Industrial Bank of Korea and Prodigy Investment.

The company offers ASCA101, which is a drug development technology that develops low-toxic anticancer drugs for cancer treatments including intractable and terminal cancers. In addition, the company also offers anticancer palliative drugs, including cancer cachexia.

The company plans to use the funds raised in April 2022 to conduct clinical trials to confirm the safety of its anticancer palliative drugs.

## Funding rounds

- Series B, Apr 28, 2022, $16M — Korea Investment & Securities, Meritz Securities, DSC Investment, IBK Capital, Prodigy Investment, Meritz Capital, S&S Investment, IP Partners, JOONG DONG FINANCE CO., LTD, BMIKOREA
- Series A, Nov 30, 2018, $8M — DSC Investment, BMIKOREA

## Investors

- DSC Investment (https://capitalatlas.ai/funds/dsc-investment) — Series A, Series B
- BMIKOREA — Series A, Series B
- Korea Investment & Securities (https://capitalatlas.ai/funds/korea-investment-securities) — Series B
- Meritz Securities — Series B
- IBK Capital (https://capitalatlas.ai/funds/ibk-capital) — Series B
- Prodigy Investment (https://capitalatlas.ai/funds/prodigy-investment) — Series B
- Meritz Capital — Series B
- S&S Investment (https://capitalatlas.ai/funds/s-s-investment) — Series B
- IP Partners (https://capitalatlas.ai/funds/ip-partners) — Series B
- JOONG DONG FINANCE CO., LTD — Series B